精神病与抗精神病治疗的心血管效应
精神障碍尤其是精神分裂症患者的心血管死亡率升高,原因涉及多个方面:抗精神病药物在传统冠脉风险因素之外还可导致心脏副作用;精神分裂症本身通过心脏自主神经功能障碍和代谢综合征高发增加心血管死亡风险。传统抗精神病药的致心律失常作用(尤其经hERG钾通道)已知,较新药物致心律失常风险较低但可能因代谢恶化增加心脏死亡率;氯氮平诱导的心肌病与剂量无关,需持续监测,ACEI预防正在评估中。
要点
- 精神分裂症患者心血管死亡率升高,与自主神经功能障碍和代谢综合征高发相关。
- 传统抗精神病药经hERG钾通道致心律失常,较新药物代谢副作用可能增加心脏死亡。
- 氯氮平诱导的心肌病与剂量无关,需持续监测,ACEI预防正在评估。
核心结论
- 精神障碍患者心血管死亡率升高,尤其精神分裂症,需综合管理心血管风险以平衡精神疾病治疗与心脏安全。
研究设计与样本
- 综述,总结精神病与抗精神病治疗的心血管效应及临床管理措施。
主要发现
- 传统抗精神病药经hERG钾通道致心律失常,较新药物致心律失常风险较低但可能因代谢恶化增加心脏死亡。
- 氯氮平诱导的心肌病与剂量无关,需持续监测。
- 精神分裂症本身通过心脏自主神经功能障碍和代谢综合征高发增加心血管死亡风险。
关键数值与推荐
- 氯氮平诱导的心肌病与剂量无关,需持续监测。
- ACEI预防正在评估中。
临床怎么用
- 对精神病患者应多层面细致管理心血管风险,在可接受的心血管风险参数内有效治疗严重精神疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mortality from cardiovascular disease is increased in people with mental health disorders in general and schizophrenia in particular. The causes are multifactorial, but it is known that antipsychotic medication can cause cardiac side-effects beyond the traditional coronary risk factors. Schizophrenia itself is a contributor to an increased risk of cardiovascular mortality via cardiac autonomic dysfunction and a higher prevalence of metabolic syndrome, both contributing to a reduced life expectancy. The pro-arrhythmic impact of traditional antipsychotics, especially via the hERG-potassium channel, has been known for several years. Newer antipsychotics have a reduced pro-arrhythmic profile but might contribute to higher cardiac death rates by worsening the metabolic profile. Clozapine-induced cardiomyopathy, which is dose independent, is a further concern and continuous monitoring of these patients is required. Prophylaxis with angiotensin-converting enzyme inhibitors is currently under review. Overall, management of cardiovascular risk within this population group must be multifaceted and nuanced to allow the most effective treatment of serious mental illness to be conducted within acceptable parameters of cardiovascular risk; some practical measures are presented for the clinical cardiologist.
引用
- Howell S, Yarovova E, Khwanda A, et al. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart. 2019. PMID: 31439658. doi:10.1136/heartjnl-2017-312107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。